Broadalumab the other IL-17 inhibitor, is FDA approved for psoriasis. The AMVISION-1 & AMVISION-2 ph III trials in psoriatic arthritis showed in 962 PsA pts it was effective w/ week 16 ACR20 of ~46% (vs 21% PBO). AEs unremarkable w/ 1 case of depression https://t.co/zrsVD7N3Z9